-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：我們將GPI的12個月目標價下調10美元至375美元，基於2027年7.9倍的市盈率，略高於GPI過去10年的平均預期市盈率7.7倍。我們將2026年調整後每股盈餘預期從44.40美元下調至41.50美元，2027年調整後每股盈餘預期從48.40美元下調至47.70美元。鑑於GPI近期業績異常疲軟，我們維持對GPI股票的「持有」評級。在發布財報之前，GPI過去八年的季度獲利超過預期90%以上，但第一季銷售額令人失望，導致獲利大幅低於預期，因此我們維持「持有」評級。不過，值得欣慰的是，GPI英國業務的業績有所改善。從正面的方面來看，GPI繼續積極透過股利和股票回購向股東返還現金，第一季回購了1.7%的流通股。汽車經銷商的基本面依然嚴峻，本季GPI的獲利連續第三季未達預期，而該公司先前曾擁有汽車零售業最佳的獲利紀錄之一。
Related Articles
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Labcorp Holdings Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $300 from $325, 16.6x our 2026 EPS estimate, a premium to LH's three-year historical forward average of 15.3x, supported by our favorable view for health care services, including healthy lab testing volume growth within an environment of high medical utilization, as well as attractive growth prospects given new therapies and aging demographics, in our opinion. We raise our 2026 EPS estimate to $18.03 from $17.90 and raise our 2027 estimate to $19.32 from $19.15. Q1 2026 acquisitions were $202 million, including operations from Crouse Health's Laboratory Alliance of Central New York, while management expressed confidence in the upcoming deal pipeline during the Q1 earnings conference call. Acquisitions totaled $582 million during 2025. LH anticipates a 30 bps headwind for diagnostics volumes in 2026 due to the recent expiration of ACA enhanced premium tax credits, which we expect to cause a meaningful drop in ACA exchange insurance coverage.
$LH
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Cardinal Health Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $225 from $260, 19.3x our FY 27 EPS estimate (up $0.24 to $11.66; FY 26 estimate up to $10.75 from $10.28), a premium to CAH's one- and three-year historical forward averages of 17.2x and 14.7x, respectively, to reflect our favorable outlook for pharmaceutical distributors.
$CAH
Research
Research Alert: CFRA Maintains Buy Opinion On Shares Of Blue Owl Capital Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We reduce our 12-month target price by $5 to $15, applying a more conservative equity risk premium and a forward P/E of 15.0x compared to the three-year historical average on 2026 earnings at 19.4x. We reduce our 2026 distributable earnings (DE) by $0.05 to $0.95 and 2027's by $0.10 to $1.05. We have seen negative investor sentiment on private credit, OWL's redemptions from retail investor, and direct loan exposure to technology and professional services businesses potentially hurt by AI disruption. However, fundamentals in private credit markets and specifically direct loans remain stable, with no signs of systemic risk or any indicators that loan delinquencies are accelerating. OWL has a diversified portfolio evident with direct loans representing only 37% of total AUM at $315B. In Q1 2026, fundraising rose to $44.4B Y/Y compared to $29.4B a year ago, and Private Credit was up $20.8B, +40% Y/Y (47% of total fundraising). Private Wealth fundraising was only $2.9B, mostly in Real Assets and Private Credit.
$OWL